In a prospective, multicenter study, the 31-GEP identified patients at increased risk of tumor recurrence and added significant prognostic value to AJCC staging. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s504, 2024. DOI: 10.25251/skin.8.supp.504. Disponível em: https://skin.dermsquared.com/skin/article/view/3058. Acesso em: 18 may. 2025.